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Introduction
The incidence of obesity induced insulin resistance and type 2 diabetes mellitus increases. Lipid infusion studies in healthy subjects showed that increased plasma free fatty acids (FFA) reduce insulin-mediated glucose uptake (1) . Plasma FFA levels correlate with intramyocellular triglycerides (IMTG) during lipid infusion (2) and IMTG correlate negatively with peripheral insulin sensitivity (3) .
Various metabolites of FFA, such as ceramide, have been suggested to decrease insulin sensitivity in skeletal muscle (4) . Increased muscle ceramide concentrations have been reported to correlate negatively with insulin sensitivity in obese insulin resistant subjects (5) . Intracellular ceramide synthesis from palmitate is a mechanism by which FFA decrease insulin-stimulated phosphorylation of protein kinase B/AKT (AKT) (6) .
During short-term fasting, plasma FFA (7) as well as intramyocellular lipid stores increase (8) . Also, fasting induces insulin resistance although the exact mechanism is still unknown (9;10). Fasting increases intramyocellular ceramide levels in rats (11) , but this has not been investigated in lean healthy humans. Therefore, we studied peripheral glucose metabolism during hyperinsulinemic euglycemic clamp conditions in healthy lean subjects after 14 and 62 h of fasting in relation to muscle ceramide and phosphorylation of AKT at serine 473 (pAKT-ser 473 ). We hypothesized that fasting increased muscle ceramide and decreased peripheral insulin sensitivity via lower muscle pAKT-ser 473 levels.
Subjects and methods

Subjects
After informed consent, eight healthy, non smoking, male volunteers were included. The study was approved by the Medical Ethical Committee of the Academic Medical Center.
Protocol
Subjects were studied after 14 and 62 h of fasting, separated by at least a week. Subjects fasted from 2000 h the evening before the first study day and from 2000 h three days before the second study day. Glucose kinetics (tracer: [6,6-2 H 2 ]glucose; >99% enriched; Cambridge Isotopes, Andover, USA: prime, 8.8 μmol/kg; continuous, 0.11 μmol/kg·min), FFA and glucoregulatory hormones were measured in the basal state and after a 5 h hyperinsulinemic euglycemic clamp (insulin infusion: 60mU/m 2 ·min; Actrapid 100 IU/ 48 ml; Novo Nordisk Farma B.V., Alphen aan den Rijn, the Netherlands) as described earlier (12) . Insulin infusion rates were chosen to completely suppress endogenous glucose production (13) .
Indirect calorimetry (O 2 consumption and CO 2 production) and muscle biopsies were performed at the end of both basal state and clamp as described previously (12) .
Analytical Procedures
Plasma glucose and FFA concentrations were measured as reported earlier (12) . [6, 
glucose enrichment was measured as described previously (12) .
Insulin, cortisol, glucagon and catecholamines were determined as described previously (12) . Soluble tumor necrosis factor receptors (sTNF-R) I and II were determined with an EASIA kit (Biosource Europe S.A., Belgium).
Ceramide in muscle biopsies was measured as described previously (12) . 
Calculations and statistics
Endogenous glucose production (EGP) and peripheral glucose uptake (rate of disappearance/Rd) were calculated with modified forms of the Steele Equations as described (12) . Glucose oxidation was calculated as reported previously (12) . Glucose kinetics, FFA and glucoregulatory hormones ( Table 1) Basal plasma glucose concentrations, glucose oxidation and EGP were significantly lower after 62 h of fasting, whereas basal plasma FFA increased significantly.
Comparisons and correlations were performed with the Wilcoxon Signed Rank test and
No differences were found in plasma glucose concentrations between clamps. Rd was significantly lower after 62 h of fasting. Non-oxidative (NOGD) glucose disposal and oxidative glucose disposal during the clamp was lower after 62 h. Glucose oxidation and NOGD expressed as percentage of Rd did not differ between clamps. Plasma FFA were equally suppressed during both clamps.
Insulin levels were lower after 62 h of fasting in the basal state and during the clamp.
Glucagon levels were higher in the basal state and tended to be higher during the clamp after 62 h of fasting. Fasting did not influence plasma cortisol and norepinephrine levels.
Plasma epinephrine concentrations, however, were higher after 62 h of fasting in the basal state but not during the clamp. sTNF-RI and II did not change.
Muscle measurements
Muscle ceramide concentrations in the basal state tended to be higher after 62 h of pmol/mg wet weight respectively, P = 0.5.
Insulin-mediated peripheral glucose uptake and muscle ceramide levels did not pGSK-3-ser 9 was not different between basal states or clamps, but increased significantly during the clamps.
Discussion
We studied the adaptation to 62 h of fasting in healthy lean men to explore the mechanism underlying the fasting induced decrease in peripheral insulin sensitivity.
Our study confirms reports on lower glucose concentrations, EGP and peripheral insulin sensitivity after fasting (9;10). The lower NOGD after fasting, supports data by Bergman et al (9) . However not all studies detected changes in NOGD during fasting (14) . If glucose oxidation and NOGD were expressed as percentage of Rd, no differences were found, suggesting that the intracellular fate of glucose remains intact despite decreased peripheral glucose uptake.
To further explore the fasting induced insulin resistance, we examined muscle ceramide.
The trend towards increased muscle ceramide levels in the basal state after 62h of fasting suggests a fasting effect, but hinders a definite assumption. Muscle ceramide is mainly derived from de novo synthesis from serine and palmitate (6) . We found no correlation of muscle ceramide with plasma FFA levels, suggesting that de novo synthesis is not the denominator of muscle ceramide during short-term fasting (12) .
Sphingomyelin hydrolysis, another pathway resulting in ceramide generation, occurs under stress stimuli like TNFα (6) . However, we found no changes in plasma sTNF-RI and II. Also, we earlier reported no changes in inflammatory parameters during fasting (10) . Therefore, the trend for higher muscle ceramide levels within skeletal muscle after fasting remains unexplained.
AKT is a 56 kD serine/threonine kinase and a mediator of many insulin effects and its regulation is complex (15) . To be activated, AKT is translocated to the plasma membrane via its PH domain that binds PI 3,4,5 P 3 , the product of phosphoinositol-3-kinase (PI3K).
Here phosphorylation of serine 473 by 3-phosphoinositide dependent kinase (PDK) 2 (16) and threonine 308 (thr 308 ) by PDK1 occur (15) . We found a significant lower ratio pAKT- (17) . Another study found no differences in pAKT-ser 473 between patients with type 2 diabetes and healthy matched controls (18) .
This indicates that the impairment in insulin signaling during fasting differs from the impairment during elevation of plasma FFA by lipid infusion or obesity. Whether the lower pAKT-ser 473 /tAKT during hyperinsulinemia is attributed to the trend to higher muscle ceramide levels in the basal state remains unanswered, since we found no correlation of ceramide levels with peripheral insulin sensitivity in line with previous observations (12;19) . Other lipid mediators such as diacylglycerol (DAG) or GM3 may interfere with the insulin signaling cascade (4): fasting increases muscle DAG in animals (11) .
AKT phosphorylates both AS160 and GSK. AS160 is involved in the insulin induced translocation of GLUT4; moreover insulin mediated phosphorylation of AS160 was shown to be decreased in patients with type 2 diabetes (18) . Phosphorylation of GSK by AKT stimulates glycogen synthesis (20) . The equal pGSK-3-ser 9 during the clamps are in line with the NOGD (as percentage of Rd) and suggests differential regulation of downstream events by AKT since pAS160-thr 642 and peripheral insulin sensitivity were lower after 62 h of fasting. A remarkable finding in our study was the lower insulin levels during the clamp after 62 h of fasting. Insulin infusions were almost identical during both clamps. It is unlikely that endogenous insulin secretion was stimulated at these euglycemic conditions.
Plasma clearance of infused insulin is mainly renal in contrast to the first pass effect of endogenous insulin by the liver (21) . Earlier studies showed equal insulin levels and lower Rd after fasting, making fasting induced insulin resistance widely accepted (9) . The insulin dose response curve negates, that the different plasma insulin levels account for differences in Rd (13) .
In conclusion, short-term fasting induces peripheral insulin resistance of glucose uptake while the muscle fate of glucose stays intact. Muscle ceramide tends to increase during fasting. The decreased peripheral glucose uptake is explained by a decrease in pAKTser 473 /tAKT and pAS160-thr 642 during the clamp.
Since studies in obesity induced insulin resistance and type 2 diabetes mellitus have not shown effects on pAKT-ser 473 , it is possible that pAKT-ser 473 is involved in the physiological adaptation to fasting, inducing a reduction in peripheral glucose uptake and protecting the body from hypoglycemia.
